Dendritic-cell-based therapeutic vaccination against cancer

被引：163

作者：

Nestle, FO ^{[1
]}

Farkas, A ^{[1
]}

Conrad, C ^{[1
]}

机构：

[1] Univ Zurich Hosp, Dept Dermatol, CH-8091 Zurich, Switzerland

来源：

CURRENT OPINION IN IMMUNOLOGY | 2005年 / 17卷 / 02期

关键词：

D O I：

10.1016/j.coi.2005.02.003

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Early clinical trials, in which over 1000 cancer patients received dendritic cell (DC) vaccines, tested different vaccine preparations, but they did not always induce sufficient acquired immunity or meet the expected level of tumor regressions. Current studies aim to improve the DC vaccine approach and capture the potential of these cells in order to gain access to lymphoid tissues and induce strong cell-mediated immunity. DC clinical trials are moving towards a more professional environment, in accordance with the latest quality standards. This explains the current need for innovative well designed trials with defined endpoints that induce robust anti-tumor immunity.

引用

页码：163 / 169

页数：7

共 67 条

[21] Prolonged IFN-γ-producing NKT response induced with α-galactosylceramide-loaded DCs
Fujii, S
Shimizu, K
Kronenberg, M
Steinman, RM
[J]. NATURE IMMUNOLOGY, 2002, 3 (09) : 867 - +
[22] Detection and activation of human Vα24+ natural killer T cells using α-galactosyl ceramide-pulsed dendritic cells
Fujii, S
Shimizu, K
Steinman, RM
Dhodapkar, MV
[J]. JOURNAL OF IMMUNOLOGICAL METHODS, 2003, 272 (1-2) : 147 - 159
[23] Induction of potent antitumor immunity by in situ targeting of intraturnoral DCs
Furumoto, K
Soares, L
Engleman, EG
Merad, M
[J]. JOURNAL OF CLINICAL INVESTIGATION, 2004, 113 (05) : 774 - 783
[24] Intranodal injection of semimature monocyte-derived dendritic cells induces T helper type 1 responses to protein neoantigen
Gilliet, M
Kleinhans, M
Lantelme, E
Schadendorf, D
Burg, G
Nestle, FO
[J]. BLOOD, 2003, 102 (01) : 36 - 42
[25] Polyclonal CTL responses observed in melanoma patients vaccinated with dendritic cells pulsed with a MAGE-3.Al peptide
Godelaine, D
Carrasco, J
Lucas, S
Karanikas, V
Schuler-Thurner, B
Coulie, PG
Schuler, G
Boon, T
Van Pel, A
[J]. JOURNAL OF IMMUNOLOGY, 2003, 171 (09) : 4893 - 4897
[26] Dendritic cells charged with apoptotic tumor cells induce long-lived protective CD4+ and CD8+ T cell immunity against B16 melanoma
Goldszmid, RS
Idoyaga, J
Bravo, AI
Steinman, R
Mordoh, J
Wainstok, R
[J]. JOURNAL OF IMMUNOLOGY, 2003, 171 (11) : 5940 - 5947
[27] Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients
Hodi, FS
Mihm, MC
Soiffer, RJ
Haluska, FG
Butler, M
Seiden, MV
Davis, T
Henry-Spires, R
MacRae, S
Willman, A
Padera, R
Jaklitsch, MT
Shankar, S
Chen, TC
Korman, A
Allison, JP
Dranoff, G
[J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2003, 100 (08) : 4712 - 4717
[28] Freeze-thawing procedures have no influence on the phenotypic and functional development of dendritic cells generated from peripheral blood CD14+ monocytes
Hori, S
Heike, Y
Takei, M
Maruyama, M
Inoue, Y
Lee, JJ
Kim, HJ
Harada, Y
Kawai, H
Shimosaka, A
Kami, M
Tanosaki, R
Wakasugi, H
Saito, S
Takaue, Y
Kakizoe, T
[J]. JOURNAL OF IMMUNOTHERAPY, 2004, 27 (01): : 27 - 35
[29] Prostaglandin E2 is a selective inducer of interleukin-12 p40 (IL-12p40) production and an inhibitor of bioactive IL-12p70 heterodimer
Kalinski, P
Vieira, PL
Schuitemaker, JHN
de Jong, EC
Kapsenberg, ML
[J]. BLOOD, 2001, 97 (11) : 3466 - 3469
[30] Kinetics of dendritic cell activation:: impact on priming of TH1, TH2 and nonpolarized T cells
Langenkamp, A
Messi, M
Lanzavecchia, A
Sallusto, F
[J]. NATURE IMMUNOLOGY, 2000, 1 (04) : 311 - 316

← 1 2 3 4 5 6 7 →